HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

lysine(6)- glutaryl- 2- (hydroxymethyl)anthraquinone LHRH (T 98)

cytotoxic LHRH agonist; less toxic than G-HMAQ by itself
Also Known As:
T 98; T-98; LHRH, lysine(6)-glutaryl-2-(hydroxymethyl)anthraquinone; Lys(6)LHRH-glutaryl-2-(hydroxymethyl)anthraquinone; Luteinizing hormone-releasing factor (pig), 6-(N6-(5-((9,10-dihydro-9,10-dioxo-2-anthracenyl)methoxy)-1,5-dioxopentyl)-D-lysine)-
Networked: 15 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Bylsma, Sophia: 1 article (12/2022)
2. Huang, Chiung-Yu: 1 article (12/2022)
3. Kambhampati, Swetha: 1 article (12/2022)
4. Kennedy, Vanessa: 1 article (12/2022)
5. Lo, Mimi: 1 article (12/2022)
6. Martin, Thomas: 1 article (12/2022)
7. Natsuhara, Kelsey: 1 article (12/2022)
8. Shah, Nina: 1 article (12/2022)
9. Sheng, Ying: 1 article (12/2022)
10. Wolf, Jeffrey: 1 article (12/2022)

Related Diseases

1. Glioma (Gliomas)
2. Neoplasms (Cancer)
3. Breast Neoplasms (Breast Cancer)
01/01/1992 - "The rates of association and dissociation for [125I]T-98 were calculated to be 4.757 x 10(8) M-1 min-1 and 0.016 min-1 (t1/2 = 38.7) in membranes from MXT mammary cancer. "
01/01/1992 - "In membranes from MXT mammary cancer, T-98 bound to one class of saturable, specific, noncooperative binding sites with high affinity and low capacity. "
01/01/1992 - "Analysis of the binding data showed that in human breast cancer, interaction of [125I]T-98 was consistent with the presence of two classes of LH-RH receptors, one class showing high affinity and low capacity, and the other class showing low affinity and high capacity binding. "
01/01/1992 - "Binding kinetics and analyses of displacement curves of [125I]D-Trp6-LH-RH and [125I]T-98 in membranes of human breast cancer and estrogen independent MXT mouse mammary cancer suggest that binding of the cytotoxic analog T-98 to the LH-RH receptor proceeds reversibly like that of its congeners without cytotoxic radicals. "
01/01/1993 - "Binding capacities and apparent dissociation constants of receptors for luteinizing-hormone-releasing hormone (LHRH) were investigated in estrogen-independent MXT mammary cancers of untreated mice and after in vivo treatment with agonistic or antagonistic analogs of LHRH containing cytotoxic radicals: AJ-04 (agonist [D-Lys6]LHRH linked to methotrexate), T-98-([D-Lys6]LHRH coupled to glutaryl-2-(hydroxmethyl)anthraquinone (G-HMAQ)) and T-121/B (LHRH antagonist T-147 containing two residues of G-HMAQ), which induced tumor growth inhibition. "
4. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
5. Substance-Related Disorders (Drug Abuse)

Related Drugs and Biologics

1. Gonadotropin-Releasing Hormone (GnRH)
2. Estrogens (Estrogen)
3. Anthraquinones
4. glutaryl-2-(hydroxymethyl)anthraquinone
5. Methotrexate (Mexate)
6. lysine(6)- glutaryl- 2- (hydroxymethyl)anthraquinone LHRH (T 98)
7. ErbB Receptors (EGF Receptor)
8. Small Interfering RNA (siRNA)
9. Memantine (Namenda)
10. C-Reactive Protein

Related Therapies and Procedures

1. Ovariectomy (Oophorectomy)
2. Length of Stay
3. Subcutaneous Injections
4. Castration